Rui Jorge Nobre holds a degree in Biology (2002) and a PhD in Health Sciences and Technology (Biotechnology, 2009) from the University of Coimbra. During his PhD, he conducted research at the Portuguese Institute of Oncology and at the German Cancer Research Center (DKFZ, Heidelberg), where he discovered and characterized a novel oncogenic human papillomavirus.

Since 2010, he has been a researcher at the Center for Neuroscience and Cell Biology (CNC-CIBB), University of Coimbra, focusing on gene therapy and viral vector platforms for neurodegenerative diseases. He is currently an Assistant Researcher and Coordinator of ViraVector, a national infrastructure supporting the development and production of viral vectors for advanced therapies.

His research focuses on AAV-based gene therapy targeting the central nervous system, particularly in Machado–Joseph disease, with a strong emphasis on translational development. He has authored over 80 peer-reviewed publications, is the inventor of 7 patent applications, and has secured approximately €2 million in competitive research funding.

He has established collaborations with academic and industrial partners and contributes actively to training and supervision of MSc and PhD students.